George Goshua, MD, MSc, FACP
Assistant Professor of Medicine (Hematology)Cards
About
Research
Overview
As in 2017, in 2021 the United States again ranked #11/11 both on overall performance and across several domains of health care system performance in The Commonwealth Fund's reports "Mirror, Mirror 2017"and "Mirror, Mirror 2021". These rankings are despite the known, decades-long breakaway #1 global ranking in healthcare spending as percentage of GDP. Our consistent #11/11 rankings in the domains of Access (i.e., affordability and timeliness), Equity (i.e., difference between low- and high-income individuals), and Healthcare Outcomes (i.e., population health, mortality amenable to health care, disease-specific health outcomes) are particularly amenable to resource allocation optimization. That is, delivering affordable and equitable care at the right time to the right individuals. Decision analytic modeling allows an explicit quantification of effect estimates, precision intervals and uncertainty present in any given medical decision where tradeoffs are present. The United States' clinical hematologic-oncologic space is particularly rife with new, expensive therapeutic offerings, many times with unclear effect on quality-of-life, and this is where our laboratory fuses methodologic and clinical expertise.
For practical impact of, and research accolades for, our lab's work please visit us at www.goshualab.com. Briefly for the former, this has included 1. inpatient formulary approval of rituximab for patients with immune thrombotic thrombocytopenic purpura (iTTP) in the US hospital setting, 2. clinical optimization of tocilizumab in a supply-limited context in Canada, 3. international debate as to the efficacy, safety, and consequent cost-ineffectiveness of caplacizumab in iTTP, 4. gap fill in the American Society of Hematology guidelines for optimal second-line treatment sequencing for patients with chronic immune thrombocytopenia, 5. quantitative accounting of health equity consideration for the first time in hematology oncology (in gene therapy for patients with sickle cell disease). Ongoing and planned work includes research in alloimmunization, gene therapy, maternal-fetal hematology, complement inhibition, iron deficiency, iron chelation, thrombosis, with a particular focus on the quantitative modeling of health equity considerations in all of these diseases within the United States.
Medical Subject Headings (MeSH)
Academic Achievements & Community Involvement
Clinical Care
Overview
George Goshua, MD, MSc, FACP, is a physician-scientist who specializes in hematology, diagnosing and treating various blood disorders, such as thrombosis and anemia.
Dr. Goshua runs the first health decision science laboratory focused on hematology-oncology outcomes in the United States. His research has been repeatedly awarded by the leading hematology societies, the NOMIS Foundation, and Science Magazine.
Dr. Goshua is an assistant professor of medicine at Yale School of Medicine.
Clinical Specialties
Board Certifications
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2022
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2018
News & Links
Media
- Full, most recent original science manuscript available at: https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.26497
News
- September 10, 2024
Spleen Removal as Treatment for Primary Warm Autoimmune Hemolytic Anemia
- March 20, 2024
From the journals
- December 06, 2023
New Research Sheds Light on Equitable Treatment Options for Pediatric Patients With Sickle Cell Disease
- November 28, 2023
Yale Cancer Center Experts Present New Research at Hematology Annual Meeting